Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.781
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2019
Authors
Publisher
Elsevier BV